The acquisition, Incyte’s first of an entire company, hands the pharmaceutical company a potentially long lasting treatment ...
Part of a $1 billion alliance the companies formed in 2020, the drug will be tested in a large study of patients who test ...
Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting.
The biotech said the proposed offer “significantly undervalues” the company, but that it’s open to considering a higher bid.
Vivera invites congress members combatting the opioid crisis to discuss response and prevention solutions. A recently released congressional Joint Economic Committee (JEC) report estimates that opioid ...
The regulator could soon approve medicines from Apellis, Gilead and GSK, as well as decide on whether to pull a controversial ...
The companies said the drug, called lecanemab, met all of its goals in the Phase 3 study. The data are a significant finding ...
The drug, which will be sold as Relyvrio, showed modest benefits in function and survival in testing. It also became the ...
Positive results from a late-stage clinical trial of the drug, called lecanemab, were a surprising success for a field used ...
The list price is slightly lower than another ALS therapy approved five years ago, but well above what one drug cost watchdog ...
The CEO resuscitated the sector’s first public benefit corporation during the pandemic, building an unusually transparent ...
The California biotech will receive $25 million upfront from Sanofi, which plans to use Scribe’s platform to edit natural ...